Copenhagen, Denmark, 8 March 2021 - Xellia Pharmaceuticals (‘Xellia’), a global leader in the manufacturing of specialty anti-infective treatments, has appointed Patrick Brunner as Vice President North America Manufacturing Operations and new site head at its Cleveland, Ohio manufacturing facility.
Patrick is a pharmaceutical industry operations and supply chain executive with more than 20 years of experience. He has previously led manufacturing operations for large pharmaceutical companies such as Actavis (now Allergan), Watson and Teva, and has been responsible for manufacturing sterile drugs, Active Pharmaceutical Ingredients, oral solid doses, patches and topicals. Through roles such as Senior Vice President of International Manufacturing (Actavis) and Chief Operations Officer (Theramex), he has covered more than 4,500 formulations and 17,000 stock-keeping units, at over 40 sites in 20 countries.
Patrick has been appointed to join Xellia’s North American Leadership Team in managing US drug manufacturing and supply operations. He will take on the role as site head at Xellia’s manufacturing facility in Cleveland, Ohio, where he will oversee the production of key anti-infective products.
Craig Boyd, President of Xellia’s North American Business Unit, commented: “Patrick is well-known within the pharmaceutical manufacturing industry as an experienced hands-on plant operator with a proven track record of success. I look forward to Patrick enabling commitment and infusing zest and excitement into our Cleveland manufacturing operations as we continue to ramp-up the production of essential anti-infectives for US hospitals and patients.”
Patrick Brunner, newly appointed Vice President North America Manufacturing Operations and new site head at Xellia’s Cleveland, Ohio, facility added: “I am delighted to be joining Xellia Pharmaceuticals, and the North American Leadership Team. Xellia has created an impressive anti-infective drug manufacturing network to help ensure reliable supply for US customers. I look forward to joining the team, as we strengthen and expand Xellia’s offerings; reaching more customers with both current and new products.”
Xellia has made significant investments at the Cleveland facility since its acquisition in 2015 to create a modern, world-class manufacturing site. The state-of-the-art facilities are strengthening Xellia’s ability to provide a reliable and consistent supply of vital anti-infective products across the US, with a core emphasis on quality.
In addition to manufacturing Xellia’s essential anti-infectives, the Cleveland facility offers Contract Manufacturing services for partners that are aligned with the Company’s focus; to ensure a reliable supply of critical drug products for patients in need.
For more information, please contact:
Craig Boyd, President, Xellia North America
Tel: +1 440 359 2050
Instinctif Partners (International media relations)
Melanie Toyne-Sewell / Rozi Morris / Siobhan Sanford
Tel: +44 (0) 20 7457 2020